๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

29 recruiting trials

for Neuroblastoma Recurrent

Study in Children and Adolescents of 177Lu-DOTATATE (Lutatheraยฎ) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). NCT06607692Phase 1, Phase 21 site๐Ÿ“ Boadilla del Monte Fundaciรณn de investigaciรณn HM ยท Tests: Olaparib; 177Lu-DOTATATE NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial NCT06450041Phase 213 sites๐Ÿ“ Los Angeles๐Ÿ“ San Francisco๐Ÿ“ Aurora New Approaches to Neuroblastoma Therapy Consortium ยท Tests: Universal Donor (UD) TGFฮฒi NK Cells, Temozolomide, Irinotecan, Dinutuximab, GM-CSF NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma NCT07211737Phase 11 site๐Ÿ“ Houston Baylor College of Medicine ยท Tests: i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells, i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells, i15.NKG2D.zeta NK celโ€ฆ Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse NCT07437963Phase 1, Phase 22 sites๐Ÿ“ Oakland๐Ÿ“ Chicago National Cancer Institute (NCI) ยท Tests: Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Dinutuximab APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors NCT05701306Phase 1, Phase 23 sites๐Ÿ“ Guangzhou๐Ÿ“ Wuhan๐Ÿ“ Tianjin Ascentage Pharma Group Inc. ยท Tests: APG-115, APG-2575 Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants NCT00898638n/a4 sites๐Ÿ“ Nashville๐Ÿ“ Nashville๐Ÿ“ Nashville Vanderbilt University Medical Center ยท Tests: biologic sample preservation procedure, medical chart review Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors NCT07584499Phase 11 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Becotatug Vedotin A Multi-Arm, Platform Trial For Relapsed Neuroblastoma NCT07334301Phase 1, Phase 223 sites๐Ÿ“ Sydney๐Ÿ“ Vienna๐Ÿ“ Brussels University of Birmingham ยท Tests: Bevacizumab, Dinutuximab beta, Irinotecan (drug), Topotecan, Temozolomide (TMZ) Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma NCT00107289Phase 21 site๐Ÿ“ New York Memorial Sloan Kettering Cancer Center ยท Tests: iobenguane I 131 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma NCT04903899Phase 25 sites๐Ÿ“ Copenhagen๐Ÿ“ Vilnius๐Ÿ“ Utrecht Jakob Stenman ยท Tests: 177Lu-DOTATATE Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma NCT07502287Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: EB-DTNB-NK, Fludarabine, Cyclophosphamide A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma NCT07085338Phase 25 sites๐Ÿ“ San Francisco๐Ÿ“ Aurora๐Ÿ“ Ann Arbor St. Jude Children's Research Hospital ยท Tests: Temozolomide, Irinotecan, hu14.18K322A, N803, Sargramostim Quadruple Immunotherapy for Neuroblastoma NCT05754684Phase 21 site๐Ÿ“ Hong Kong Hong Kong Children's Hospital ยท Tests: Natural killer cell, Dinutuximab beta, Interleukin-2, Granulocyte-Macrophage Colony-Stimulating Factor, Spironolactone PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors NCT06721689Phase 1, Phase 27 sites๐Ÿ“ Los Angeles๐Ÿ“ San Francisco๐Ÿ“ Boston Theodore Laetsch ยท Tests: PEEL-224, Vincristine, Temozolomide (TMZ) Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children NCT07318831Phase 21 site๐Ÿ“ Tianjin Tianjin Medical University Cancer Institute and Hospital ยท Tests: Chidamide Combined with Dinutuximab Beta, Irinotecan, and Temozolomide Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma NCT07375563Phase 31 site๐Ÿ“ Moscow Federal Research Institute of Pediatric Hematology, Oncologโ€ฆ ยท Tests: Dinutuximab beta, temozolomide, irinotecan, autologous NK cell, irinotecan, temozolomide, dinutuximab beta, NK-cell proโ€ฆ A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors NCT05135975Phase 26 sites๐Ÿ“ Birmingham๐Ÿ“ Aurora๐Ÿ“ Washington D.C. Nationwide Children's Hospital ยท Tests: Cabozantinib Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma NCT05400603Phase 11 site๐Ÿ“ Atlanta Emory University ยท Tests: Ex Vivo Expanded Allogeneic ฮณฮด T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma NCT06674265Phase 11 site๐Ÿ“ Tehran Marzieh Ebrahimi ยท Tests: Allogenic NK cells infusion Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma NCT04901702Phase 1, Phase 210 sites๐Ÿ“ Palo Alto๐Ÿ“ Aurora๐Ÿ“ Washington D.C. St. Jude Children's Research Hospital ยท Tests: Onivyde, Talazoparib, Temozolomide Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma NCT06751134Phase 12 sites๐Ÿ“ Nanjing๐Ÿ“ Nanjing Nanjing Children's Hospital ยท Tests: Chimeric Natural Killer Receptor Universal T-cells (CNK-UT) Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors NCT04851119Phase 1, Phase 221 sites๐Ÿ“ Birmingham๐Ÿ“ Los Angeles๐Ÿ“ Orange Children's Oncology Group ยท Tests: Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint, X-Ray Imaging Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors NCT02013336Phase 15 sites๐Ÿ“ Cincinnati๐Ÿ“ Oklahoma City๐Ÿ“ Dallas South Plains Oncology Consortium ยท Tests: MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma NCT07027748Phase 12 sites๐Ÿ“ Boston๐Ÿ“ Boston Steven DuBois, MD ยท Tests: Naxitamab, Irinotecan, Temozolomide, Sargramostim granulocyte-macrophage colony stimulating factor Recurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of Nivolumab NCT07100704Phase 22 sites๐Ÿ“ Kashiwa๐Ÿ“ Shimotsuke National Cancer Center Hospital East ยท Tests: Nivolumab Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma NCT06803875Phase 1, Phase 22 sites๐Ÿ“ Boston๐Ÿ“ Boston Roberto Chiarle ยท Tests: Autologous hALK.CAR T cells A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma NCT06684639EARLY Phase 11 site๐Ÿ“ Chengdu The General Hospital of Western Theater Command ยท Tests: GD2-CAR-T cell GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults NCT07087002Phase 11 site๐Ÿ“ Palo Alto Stanford University ยท Tests: GPC2-CAR T cells, Fludarabine, Cyclophosphamide Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma NCT06013618Phase 21 site๐Ÿ“ Guangzhou Sun Yat-Sen University Cancer Center ยท Tests: Naxitamab monotherapy, GM-CSF, Irinotecan, Temozolomide, Naxitamab in combination therapy
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy